A Pre-Operative Study to Assess the Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2018
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 21 Nov 2018 Planned End Date changed from 1 Oct 2022 to 1 Oct 2021.
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2018 Planned End Date changed from 1 Oct 2021 to 1 Oct 2022.